1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Jul 2024
Admin
News Article

N-Power Medicine and Merck Collaborate to Expand Oncologist and Patient Access to Clinical Trials

Overview

Alteogen Inc. (KOSDAQ: 196170) announced on July 1st that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for an aflibercept biosimilar ALT-L9, developed by Alteogen.

Phase 3 Clinical Trial

The Phase 3 clinical trial for ALT-L9 commenced with initial clinical trial approval in 2022, involving over 400 subjects across 12 countries.
The study compared efficacy, safety, and immunogenicity against Eylea® in the indication of wet Age-related Macular Degeneration.
Conducted in Europe, South Korea, and Japan, the trial evaluated changes in Best-Corrected Visual Acuity (BCVA) over an 8-week period as the primary endpoint.
The study demonstrated therapeutic equivalence between ALT-L9 and Eylea®, prompting the submission of the Marketing Authorization Application.

Altos Biologics expects to receive approval from EMA by 2025, aligned with the substance patent expiration, and intends to negotiate License Agreements with potential distributors worldwide.

Words from CEO: Alteogen

Dr. Soon Jae Park, Chief Executive Officer of Alteogen, emphasized, "The submission of Marketing Authorization Application for ALT-L9, developed by Alteogen and clinically tested by Altos Biologics, mark significant milestones in commercializing our proprietary products and gaining global clinical experience."
He added, "This represents a crucial moment for Alteogen's growth as a global pharmaceutical company."

Words from CEO: Altos Biologics

"Following the European Marketing Authorization Application for ALT-L9, we plan to pursue product approvals in target markets including Korea," added Dr. Hyi Jeong Ji, Chief Executive Officer of Altos Biologics.
Altos Biologics also aims to leverage its expertise gained from this trial in ophthalmic diseases to develop a novel multi-specific fusion protein therapeutic incorporating Tie2 regulators, in addition to anti-VEGF mechanisms similar to Eylea®, aimed at stabilizing blood vessels. This initiative aims to position the company as a leading developer of Best-in-Class treatments in the expanding market driven by aging demographics and related eye conditions.

About Alteogen Inc.

Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars.
Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively.
It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion.
The company was founded in 2008 and listed in KOSDAQ (196170.KQ).

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!